-

Palleon Pharmaceuticals to Present at the Oppenheimer Healthcare Private Company Showcase

WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that the company will present at the Oppenheimer Healthcare Private Company Showcase: The Next Wave on Tuesday, October 18, 2022. Jim Broderick, M.D., Chief Executive Officer and founder of Palleon, will present a company overview at 11:45am PT and Palleon will host 1x1 investor meetings, which can be requested through Oppenheimer.

About Palleon Pharmaceuticals
Palleon Pharmaceuticals, co-founded by Nobel laureate Carolyn Bertozzi, is a biotechnology company pioneering glyco-immunology drug development to transform the treatment of cancer and inflammatory diseases. The Company’s proprietary platforms overcome technical barriers unique to glycobiology to enable drug discovery, patient selection, and indication prioritization to de-risk clinical development. The company’s lead program in oncology, E-602, is a Phase 1/2, first-in-class, glyco-immune checkpoint inhibitor which restores antitumor immunity by enzymatically degrading immunosuppressive sialoglycans on hypersialylated tumors and immune cells. Palleon has a rich pipeline of additional drug candidates including several advancing toward IND-enabling studies.

Contacts

Media
Thomas Stephenson
Ten Bridge Communications
thomas@tenbridgecommunications.com
(857) 244-0246

Palleon Pharmaceuticals


Release Summary
Palleon announces that the company will present at the Oppenheimer Healthcare Private Company Showcase: The Next Wave on Tuesday, October 18, 2022.
Release Versions

Contacts

Media
Thomas Stephenson
Ten Bridge Communications
thomas@tenbridgecommunications.com
(857) 244-0246

More News From Palleon Pharmaceuticals

Palleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ACR Convergence 2026

WATERTOWN, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a clinical-stage biotechnology company developing glycan editing therapeutics for autoimmune disease and cancer, today announced early proof-of-concept data for its first-in-class sialidase-Fc fusion protein HLX79/E-602 (efgitasialase alfa) in primary membranous nephropathy (pMN). The results were presented in an oral session at the American College of Rheumatology (ACR) Convergence 2026 in Orlando. Palleon’s partner, Shanghai Henlius...

Palleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ASN Kidney Week 2026

WATERTOWN, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a clinical-stage biotechnology company developing glycan editing therapeutics for autoimmune disease and cancer, today announced Phase 2 results for HLX79/E-602 (efgitasialase alfa), a first-in-class sialidase-Fc fusion protein, in primary membranous nephropathy (pMN). The data were presented today in a late-breaking oral session at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver. The randomized Phase 2 trial (NCT07...

Palleon Pharmaceuticals Announces Oral Presentation of Interim Phase 2 trial data for HLX79/E-602 in Membranous Nephropathy at the 2026 American College of Rheumatology (ACR) Convergence

WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a clinical-stage biotechnology company developing novel therapeutics for autoimmunity and cancer, will deliver an oral presentation at the 2026 American College of Rheumatology (ACR) Convergence, taking place November 6-11 in Orlando, Florida. Palleon's presentation will take place on Wednesday, November 11. Details of Palleon's Presentation: American College of Rheumatology (ACR) Convergence Title: Rapid and deep clinical responses to H...
Back to Newsroom